|Page (1) of 1 - 09/13/17||email article||print page|
Adamas to Host Investor and Analyst Meeting on September 18, 2017(September 13, 2017)
EMERYVILLE, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it will host an Investor and Analyst meeting on Monday, September 18, 2017 from 8:00 a.m. – 11:00 a.m. ET in New York, NY. The event will be hosted by members of the Adamas executive management team and will feature presentations from Key Opinion Leaders in the fields of Parkinson’s disease and Multiple sclerosis.
The event will provide an overview of the market opportunity and commercial plans for GOCOVRI™ (amantadine) extended release capsules, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. In addition, the company will provide an overview of its clinical development programs: ADS-5102, a product candidate for the treatment of multiple sclerosis walking impairment and ADS-4101, a product candidate for the treatment of partial onset seizures in patients with epilepsy.
Attendance at this event is by invitation only. For additional event details, please contact Marcy Nanus at [email protected]. A live webcast of the event can be accessed on the Investors section of the Adamas website at http://ir.adamaspharma.com/events.cfm and will be available for replay until October 18, 2017.
GOCOVRI is the first and only medicine approved by the FDA for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. For more information about GOCOVRI, including Important Safety Information, please see the full Prescribing Information available at www.GOCOVRI.com.
About Adamas Pharmaceuticals, Inc.At Adamas, we believe in the power and the promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our portfolio includes: GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; ADS-5102 in development for the treatment of multiple sclerosis walking impairment and additional indications in Parkinson’s disease, and ADS-4101, a high-dose, modified-release lacosamide in Phase 1 clinical development for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas licensed assets are currently marketed by Allergan under the brand names NAMENDA XR® and NAMZARIC®, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA.
CONTACT: Contact:Ashleigh BarretoDirector, Corporate Communications & Investor RelationsAdamas Pharmaceuticals, [email protected]